 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Agile Therapeutics, Inc. (NASDAQ:AGRX  Get Free Report) was the target of a significant drop in short interest during the month of August. As of August 31st, there was short interest totalling...

Agile Therapeutics, Inc. (NASDAQ:AGRX) Short Interest Update

Agile Therapeutics, Inc. (NASDAQ:AGRX  Get Free Report) saw a significant decline in short interest in the month of August. As of August 15th, there was short interest totalling 20,700 shares...

Agile Therapeutics, Inc. (NASDAQ:AGRX) Sees Large Decrease in Short Interest

Agile Therapeutics, Inc. (NASDAQ:AGRX  Get Free Report) was the recipient of a significant decrease in short interest in the month of August. As of August 15th, there was short interest totalling 20,700 shares, a decrease of 46.2% from the July 31st total of 38,500 shares. Currently, 1.1% of ...

Short Interest in Agile Therapeutics, Inc. (NASDAQ:AGRX) Drops By 46.2%

StockNews.com initiated coverage on shares of Agile Therapeutics (NASDAQ:AGRX  Free Report) in a research note issued to investors on Thursday. The firm issued a hold rating on the specialty pharmaceutical companys stock. Separately, HC Wainwright reiterated a buy rating and set a $12....

Agile Therapeutics (NASDAQ:AGRX) Research Coverage Started at StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of Agile Therapeutics (NASDAQ:AGRX Get Free Report) in a research note issued to investors on Thursday. The brokerage set a hold rating on the specialty pharmaceutical companys stock. Separately, HC Wainwright reissued a buy rating and set a...

Agile Therapeutics (NASDAQ:AGRX) Receives New Coverage from Analysts at StockNews.com

PRINCETON, NJ / ACCESSWIRE / August 17, 2023 / On August 9, Agile Therapeutics (NASDAQ:AGRX) released its second-quarter financial results, showing significant growth in revenue from its innovative...

Agile Says It's On Track To Hit $25-$30 Million Net Annual Revenue After A Strong Performance In Its Second Quarter

Agile Therapeutics, Inc. (NASDAQ:AGRX  Get Free Report) was the recipient of a significant decline in short interest during the month of July. As of July 31st, there was short interest totalling 38,500 shares, a decline of 45.8% from the July 15th total of 71,000 shares. Approximately 1.4% of...

Agile Therapeutics, Inc. (NASDAQ:AGRX) Short Interest Down 45.8% in July

Twirla Delivers Second Quarter 2023 Net Revenue of $5.5 Million, a 44% Increase from First Quarter 2023 Twirla Demand and Factory Sales Up 24% and 42% Respectively in Second Quarter 2023 Compared to First Quarter 2023 Gross Margin Grows to 58% in Second Quarter 2023 from 47% in First Quarter 2023 ...

Agile Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Agile Therapeutics, Inc. 2023 Q2 - Results - Earnings Call Presentation

Agile Therapeutics, Inc. (AGRX) Q2 2023 Earnings Call Transcript

Agile Therapeutics, Inc. is a healthcare company, which engages in the development and commercialization of transdermal patches. Its lead product candidate, Twirla, also known as AG200-15, is an investigational low-dose, non-daily prescription contraceptive. The company was founded by Chien Te Yen on December 22, 1997 and is headquartered in Princeton, NJ.

Watchers	19,625
52-Wk Low	$1.65
52-Wk High	$16.00

Market Cap	$3.33M
Volume (M)	47,473.00
52-Wk High	$16.00
52-Wk Low	$1.65

AGRX Agile Therapeutics Inc

About

Feed

News

Earnings

Fundamentals